Sichenzia Ross Friedman Ference LLP Advises Laidlaw & Company on $10 million Secondary Public Offering of Cyclacel Pharmaceuticals, Inc.
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Laidlaw & Company (UK) Ltd. as sole underwriter in a $10 million secondary public offering for Cyclacel Pharmaceuticals, Inc. (“CYCC.” NASDAQ). The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of 2,857,143 shares of common stock at an offering price of $3.50 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Richard Friedman and Stephen Cohen.
- Sichenzia Ross Ference LLP Represents Borqs Technologies, Inc. in $27 Million Private Placement - September 23, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp in $15 Million Registered Direct Offering of Molecular Data Inc. - September 22, 2021
- Sichenzia Ross Ference LLP Represents EzFill in $28.75 Million Initial Public Offering and NASDAQ Listing - September 20, 2021